Sep 04, 2022 by The Beat Maker - 0 Comments
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial The Lancet
source